Genistein in Treating Patients With Localized Prostate Cancer Who Are Planning to Undergo Radical Prostatectomy

Inclusion Criteria

• •DISEASE CHARACTERISTICS:
• •Diagnosis of localized prostate cancer
• •* Diagnosed within the past 6 months
• •* T1 or T2 disease
• •* Gleason score 5-8
• •* Prostate-specific antigen no greater than 20 ng/mL
• •Radical prostatectomy planned
• •PATIENT CHARACTERISTICS:
• •Age
• •18 and over
• •Performance status
• •ECOG 0-1
• •Life expectancy
• •More than 2 years
• •Hematopoietic
• •Hemoglobin greater than 9.0 g/dL
• •Platelet count greater than 100,000/mm\^3
• •Absolute neutrophil count greater than 1,000/mm\^3
• •Hepatic
• •SGPT and SGOT less than 3 times normal
• •Bilirubin less than 3 mg/dL (less than 1.5 times normal) (patients with an elevated bilirubin due to a familial defect in bilirubin metabolism will be considered on an individual basis)
• •Renal
• •Creatinine less than 2.0 mg/dL
• •Cardiovascular
• •No venous thrombosis within the past year
• •Other
• •Patients must use effective barrier contraception
• •No other medical condition that would preclude study therapy
• •No known soy intolerance
• •PRIOR CONCURRENT THERAPY:
• •Biologic therapy
• •Not specified
• •Chemotherapy
• •Not specified
• •Endocrine therapy
• •No concurrent hormonal therapy for prostate cancer
• •Radiotherapy
• •Not specified
• •Surgery
• •See Disease Characteristics
• •Other
• •No concurrent soy supplements
• •No concurrent foods high in genistein
• •No concurrent active therapy for neoplastic disorders